Nonselective beta-blockers (NSBBs) have played an important role in the prevention of portal hypertensive bleeding in patients with cirrhosis. However, recent studies have suggested that NSBBs may be harmful in some patients with end-stage liver disease. The purpose of this article is to evaluate the association between use of NSBB and the incidence of acute kidney injury (AKI). We conducted a nested case-control study in a cohort of liver transplant wait-list registrants. Each patient with AKI was matched to a control by the Model for End-Stage Liver Disease-Na score, age, serum creatinine, and follow-up duration. Out of a total of 2361 wait-list registrants, 205 patients developed AKI after a median follow-up duration of 18.2 months. When compared with matched controls, ascites (79.0% versus 51.7%) and non-Caucasian race (16.6% versus 7.8%) were more common among the cases. The frequency of NSBB use was higher among the cases than controls, albeit insignificantly (45.9% versus 37.1%; P 5 0.08). In multivariate analyses, the impact of nonselective beta blockade on the development of AKI was dependent on the presence of ascites: nonselective beta blockade in patients with ascites significantly increased the risk of AKI (hazard ratio [HR], 3.31; 95% confidence interval [CI], 1.57-6.95), whereas in patients without ascites, NSBB use reduced it (HR, 0.19; 95% CI, 0.06-0.60). Potential benefits and harms of a NSBB in terms of AKI depend on the presence of ascites in liver transplant candidates. NSBB therapy in patients with cirrhosis may need to be individualized.
gastroesophageal varices.
(1) A number of randomized clinical trials have shown the efficacy of NSBBs in primary and secondary prevention of variceal hemorrhage. (2) (3) (4) (5) (6) NSBBs have been associated with improved survival, particularly when their use results in satisfactory reduction in the hepatic vein portal pressure gradient (HVPG). (7) (8) (9) (10) In patients with cirrhosis, development of renal dysfunction represents an important landmark in their disease progression. For example, hepatorenal syndrome (HRS), particularly of type 1, is a serious complication with a high risk of mortality. HRS is thought to result from the pervasive hemodynamic changes that occur in patients with cirrhotic portal hypertension, including splanchnic vasodilation and hypoperfusion of renal vasculature. More recently, standardized definitions of acute kidney injury (AKI) have been increasingly applied in patients with cirrhosis with evidence of decreased renal function. (11) Abbreviations: AIH, autoimmune hepatitis; AKI, acute kidney injury; ALD, alcoholic liver disease; CI, confidence interval; GFR, glomerular filtration rate; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; HRS, hepatorenal syndrome; HVPG, hepatic vein portal pressure gradient; INR, international normalized ratio; IQR, interquartile range; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; NSBB, nonselective beta-blocker; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; SBP, spontaneous bacterial peritonitis; SD, standard deviation.
Worsening stages of AKI in patients with cirrhosis are associated with a progressive increase in mortality risk. (12) The effect of nonselective beta blockade on development of renal dysfunction in patients with cirrhosis is uncertain. Earlier studies, which mainly included patients with compensated cirrhosis, reported that the hemodynamic response to a NSBB is associated with reduced risk of developing ascites, refractory ascites, and HRS. (2) More recently, in patients who have had spontaneous bacterial peritonitis (SBP) and end-stage liver disease, NSBB use was associated with higher incidence of HRS and AKI. (13, 14) One potential explanation for these contradictory observations may be that the effects of NSBBs on the kidney may be dependent on the severity of hepatic decompensation-there is a finite time "window" in which NSBBs are clinically beneficial. (15) In this work, we hypothesized that the hemodynamic effects of NSBBs, including reduced arterial blood pressure and cardiac output, may increase the risk of renal hypoperfusion and AKI in susceptible patients with cirrhosis. Our primary aim was to examine whether longterm use of a NSBB is associated with development of AKI in patients with cirrhosis waitlisted for liver transplantation. Specifically, we compare the use of NSBBs between patients with cirrhosis who develop AKI and those who did not. Second, we determine risk factors that contribute to the occurrence of AKI. In particular, we try to figure out whether renal effects of NSBBs may be dependent on the severity of hepatic decompensation.
Patients and Methods

STUDY DESIGN/PATIENTS
This is a nested case-control study derived from a cohort of liver transplant candidates. The parent cohort consisted of all adult patients with liver cirrhosis who were wait-listed for liver transplantation at Mayo Clinic, Rochester, MN, between January 1990 and December 2010. The long period covered in this study was to maximize its statistical power, namely, the number of patients developing AKI. Although the outcome of patients with portal hypertension may have improved incrementally during the period, no substantial change in the medical management of patients with cirrhosis occurred to the extent to have altered the biological relationship between beta blockade and AKI. The study was approved by the institutional review board of the Mayo Foundation.
A nested case-control study design preserves advantages of a cohort study while avoiding potential biases of a conventional case-control study. Because the cases and controls come from the same population, causal relationship could be assessed appropriately between exposure (ie, NSBB) and outcome (ie, AKI). Each AKI case was individually matched to a control by a number of variables that may confound the incidence of AKI. They included age, serum creatinine, and Model for End-Stage Liver Disease (MELD)-Na (16) at baseline and follow-up duration. As exact matching in all of these variables was not feasible, an allowable window of tolerance was defined for each variable (see Table 1 for details). Most of the data used in the study were extracted from an institutional transplant database which has been described previously. (17) In both cases and controls, individual medical records were reviewed to obtain clinical details of NSBB use.
Cases were defined as patients developing de novo AKI stage 2 during the follow-up. (18, 19) In order for a patient to be designated to be a case, the following criteria had to be met: The urine output component of the AKI definition was not applied, because necessary data were not available. Patients with prior history of kidney or liver transplantation or abnormal renal function (serum creatinine 1.5 mg/dL) or receiving hemodialysis at baseline were excluded. Patients with incomplete information about the use of NSBBs were also excluded from the analysis. Patients were censored upon liver transplantation, death, or at the end of follow-up in the absence of AKI. These events were verified with the information from the medical records and registration data.
DATA ANALYSIS
The goal of the analysis was to compare the proportions of patients receiving NSBBs between cases and controls. Thus, the primary predictor variable in this study was the use of a NSBB. This was operationally defined as having received a NSBB both at baseline and on the day of occurrence of AKI in cases and on the last day of observation in controls. This was because it is practically impossible to obtain an active medication list and ascertain its accuracy at all times in the medical record. Recent data reassure that short-term interruption of a NSBB does not affect clinical or hemodynamic status of a patient with cirrhosis. (20) In examining the applicability of the "window" concept, analyses were stratified by the presence of ascites detected by imaging (eg, ultrasonography or computed tomography) or by the use of diuretics with a history of ascites.
In comparing cases and controls, the proportional hazards regression analysis was performed to identify predictors of AKI. Given the study design, all analyses were undertaken stratifying on the matches. Unadjusted Cox models were created for demographic (age, sex, and race), major clinical variables (liver cancer, diabetes, esophageal varices, ascites), and laboratory parameters (total bilirubin, international normalized ratio [INR] , creatinine, sodium) as well as MELD-Na and NSBB use. Multivariate Cox regression was performed based on variables with unadjusted P values < 0.1. In addition, variables used in matching, namely, age, MELD-Na, and serum creatinine were included in order to control for any residual confounding. Adjusted Kaplan-Meier curves were created to compare the survival rates among patients according to the ascites and NSBB status. Analyses were implemented using SAS, version 9.3 (SAS Institute Inc., Cary, NC) and R, version 3.0.2 (R Foundation, Vienna, Austria) statistical software packages.
Results
PATIENT CHARACTERISTICS
Out of the cohort of 2361 wait-list registrants, 252 patients developed AKI and 205 patients met the specified eligibility criteria. Figure 1 represents a flow diagram illustrating the process by which cases and controls were selected. Table 1 compares baseline characteristics of the cases and controls. The median follow-up duration was 18.2 months (range, 1.0-198.2 months). The most common etiology of liver cirrhosis was viral hepatitis (26.8%). The mean (6 standard deviation [SD]) age was 52.2 6 9.6 years with a slight female preponderance (52.9%) and Caucasian majority (87.8%). According to the matching algorithm, 205 patients who did not meet the criteria for AKI were selected as controls. When compared with matched controls without AKI, ascites (79.0% versus 51.7%) and nonCaucasian race (16.6% versus 7.8%) were noticeably more common among the cases. However, no significant difference was found in age, sex, MELD score, diabetes mellitus, presence of esophageal varices between the 2 groups.
USE OF NSBBs IN CASES AND CONTROLS
Cases and controls combined, a total of 170 patients received NSBBs for the prevention of portal hypertensive bleeding. The initial NSBB prescribed was propranolol in 81 patients and nadolol in 89 patients. There were 9 patients who were switched from 1 NSBB to another, including 6 patients switching from propranolol to nadolol. Overall, the frequency of NSBB use was higher, although nonsignificantly, among the cases than the controls (45.9% versus 37.1%, respectively). 
NSBB USE AND THE RISK OF DEVELOPING AKI
In the unadjusted proportional hazard regression analysis for predicting the development of AKI (Table 2) , non-Caucasian race, high MELD and MELD-Na scores at baseline, and presence of ascites were associated with an increased risk of AKI, whereas autoimmune etiology was associated with a decreased risk. In investigating whether the incidence of AKI differs between the cases and controls depending on the presence of ascites, patients were divided into 4 groups, namely, NSBB users and nonusers with and without ascites, respectively. Figure 2 shows that the incidence of AKI is higher, as expected, among the 2 groups of patients with ascites than in those without. More importantly, the effect of NSBB was in the opposite direction between patients with and without ascites. Among patients with ascites, NSBB users experienced a higher incidence of AKI, whereas among those without ascites, the incidence of AKI was much lower in NSBB users, compared with those not taking a NSBB. Table 3 formally examines the effect of NSBB and ascites on the risk of AKI with the multivariate Cox regression analysis. After adjusting for demographic variables, MELD-Na at baseline was associated with significantly increased hazards of developing AKI (hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.36-2.03; P < 0.01). As suggested by Fig. 2 , there was a significant interaction between NSBB and ascites: NSBB use in patients with ascites increased the risk of AKI by over 3-fold (HR, 3.31; 95% CI, 1.57-6.95; P < 0.01); whereas in patients without ascites, nonselective beta blockade reduced the risk of AKI by approximately 5-fold (HR, 0.19; 95% CI, 0.06-0.60; P < 0.01).
Discussion
The main finding in this study is that the effect of NSBBs on the development of AKI in patients with cirrhosis is bidirectional depending on the presence of ascites. In patients without ascites, NSBB use was associated with an 80% reduction in AKI, whereas once ascites is present, it increased the risk of AKI by more than 3-fold. As expected, in addition to the use of a NSBB in the presence of ascites, increasing MELD-Na (or MELD) was associated with a higher incidence of AKI. Although cases and controls were matched by MELD-Na, the matching was incomplete and even within the relatively narrow range of MELD-Na scores (<7 points) allowed in matching, there still was a significant residual effect of MELDNa on the development of AKI as reported in Table 3 .
NSBBs are some of the most commonly prescribed drugs in patients with cirrhosis, as they represent a simple and relatively safe means to prevent portal hypertensive gastrointestinal bleeding. The current practice guidelines recommend early institution and indefinite continuation of NSBBs to prevent gastroesophageal variceal bleeding. (21) For example, emerging data have suggested that survival of patients with variceal hemorrhage has increased over time, (22) which may be attributed to the widespread adoption of NSBBs. However, NSBBs have several drawbacks: they may have significant adverse effects including systemic hypotension, fatigue, and shortness of breath. It is contraindicated, albeit not absolutely, in patients with asthma and insulindependent diabetes. Furthermore, NSBBs impair the patient's quality of life and reduce adherence. (15) Finally, although not all patients achieve sufficient reduction in portal hypertension, (23) HVPG is rarely monitored in practice. It remains unknown how many patients endure the side effects of their NSBB although they may not ultimately benefit from it.
FIG. 2.
Incidence of AKI according to the presence of ascites and use of NSBBs. Among patients with ascites, NSBB users experienced a higher incidence of AKI, whereas among those without ascites, the incidence of AKI was much lower in NSBB users. The potential deleterious effects of NSBBs in patients with advanced hepatic decompensation are increasingly recognized and reflected in the latest Baveno consensus. (24) In patients with ascites undergoing large-volume paracentesis, NSBBs may increase susceptibility to postparacentesis circulatory dysfunction by limiting the compensatory increase in the cardiac output. (25) (26) (27) A more recent study demonstrated that the use of propranolol was associated with reduced survival at 1 year in patients with refractory ascites (19% versus 64%) (13) and in patients with Child-Pugh C and ascites (40% versus 67%). (28) Similarly, poor outcomes were reported for NSBB use in patients who have had SBP, including shorter survival (23% versus 36% at 1 year) and increased incidence of HRS (24% versus 11% at 90 days) and AKI (20% versus 8% at 90 days). (29) Although acute deterioration in patients with cirrhosis is often precipitated by infection, nonselective beta blockade was not associated with an increased risk of serious infection in patients with compensated or decompensated cirrhosis. (30) The results of this study are in support of the recently proposed "window" concept for the beneficial effects of NSBBs. (15) With regard to renal injury, in patients without ascites, NSBBs were beneficial with reduced risk of AKI, whereas in those with ascites, NSBBs were harmful with increased risk of AKI (Fig. 3) . This observation nicely reconciles the earlier findings of NSBBs being protective with those in recent studies in which they led to worse outcomes (31, 32) because the former studies tended to include less advanced patients compared with the latter ones. According to the window concept, patients with advanced portal hypertensive complications such as refractory ascites and SBP are outside the optimal window and their risks associated with NSBBs are higher than their benefits. Our data further suggest that the window might close earlier than previously reported-NSBBs may need to be avoided in some patients with ascites prior to the onset of SBP or unresponsiveness to diuretic therapy. In those patients, endoscopic variceal ligation would provide an effective, albeit invasive, alternative to a NSBB for primary or secondary prevention of variceal hemorrhage.
At the population level, our observation may also provide some insights as to the increasing incidence of renal dysfunction in patients awaiting liver transplantation. It is recognized that more recently-in the MELD era-an increasing number of patients are requiring simultaneous liver and kidney transplantation, reflecting increased prevalence of renal dysfunction in transplant candidates. Although the fundamental drivers of this trend include worsening organ shortage and escalating MELD score needed to receive an organ and increasing awareness of the importance of renal function in liver transplant candidates, widespread use of NSBBs in patients with advanced portal hypertension may have contributed to the prevalence of renal morbidity.
We do acknowledge that there are limitations to this study. First, in this retrospective study, we were not able to accurately assess severity of ascites and all patients with ascites were lumped together. Patients with a mild degree of ascites in whom a NSBB is not detrimental could not be evaluated. Similarly, as we were not able to accurately determine the start and stop dates for NSBB usage, it was defined by its presence on the first and last days of observation. Thus, patients who were put on a beta-blocker some time after the baseline may have been misclassified. For these reasons, the authors consider our data to be insufficient to make recommendations about NSBB use in patients with ascites, especially those with uncomplicated ascites. Second, because this study was conducted among patients awaiting liver transplantation with preserved renal function, the results may not apply to patients with cirrhosis in general or those with chronic kidney disease. Furthermore, the association between nonselective beta blockade and AKI in this study may be confounded by the hemodynamic status of the patient. The direction of effect of beta blockade may not be always predictable, as patients with advanced portal hypertension who remain on NSBB may actually represent a subgroup with a better hemodynamic status. This may explain the observation by Leithead et al. (33) that NSBBs in liver transplant candidates were associated with reduced short-term (median follow-up, 72 days) wait-list death. It may be possible that detailed prospective hemodynamic data such as cardiac index, peripheral vascular resistance, and hepatic venous pressure gradient may provide additional clues to the pathogenesis of AKI in patients receiving a NSBB. In summary, this study found that NSBBs have divergent effects on renal injury depending on the severity of hepatic decompensation. Although in patients without ascites NSBBs may help preserve renal function, they increase the risk of AKI in those who already have ascites. These data add to the growing literature that there is a time window in the natural history of cirrhosis in which NSBBs are beneficial to a patient with cirrhosis. Although more detailed investigations may provide further insights to the renal hemodynamic effects of NSBBs in patients in different stages of hepatic decompensation, these data suggest that randomized controlled data are needed to derive data with which to individualize NSBB therapy in patients with cirrhosis with portal hypertension.
